TASLY(SH:600535) Jin Rong Jie·2025-08-18 23:43Group 1 - The company Tianjin Tianshi Biological Pharmaceutical Co., Ltd. has applied for a "Type III meeting" with the CDE, currently in "processing" status [1] - Type III meetings are held to discuss significant issues at critical stages and are typically scheduled within 75 days after the application [1] - Tianjin Tianshi Biological Pharmaceutical Co., Ltd. was established in 2001 and is primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of 10.8257 billion RMB and paid-in capital of 10 billion RMB [1] Group 2 - The company has made investments in three enterprises and participated in 225 bidding projects [1] - In terms of intellectual property, the company holds 2 trademark registrations and 73 patents, along with 156 administrative licenses [1] - The major shareholders of the company include Tianjin Tianshi Pharmaceutical Group Co., Ltd. holding 95% and Tianjin Tianshi Enterprise Management Co., Ltd. holding 5% [1]